Demographics of GVHD before treatment
| Characteristic . | Multidose . | Single dose . |
|---|---|---|
| No. of patients | 6 | 11 |
| Median age (y) | 40 | 24 |
| Range | 16-55 | 1-53 |
| Male/female | 6/0 | 4/7 |
| Diagnosis | ||
| ALL | 1 | 2 |
| AML/MDS | 2 | 6 |
| CML | 1 | 2 |
| NHL | 1 | 0 |
| Aplastic anemia | 1 | 0 |
| Osteopetrosis | 0 | 1 |
| Preparative regimen | ||
| Cy/TBI | 5 | 6 |
| Bu/Cy +/− ATG | 0 | 5 |
| Cy/ATG | 1 | 0 |
| GVHD prophylaxis | ||
| CSA/MTX | 6 | 9 |
| Tacrolimus/MTX | 0 | 1 |
| CSA/MP | 0 | 1 |
| Stem cell source | ||
| BM | 5 | 7 |
| PBSC | 1 | 3 |
| Cord blood | 0 | 1 |
| Donors | ||
| HLA-matched related | 3 | 1 |
| HLA-mismatched related | 1 | 1 |
| HLA-matched unrelated | 2 | 4 |
| HLA-mismatched unrelated | 0 | 5 |
| Days from transplantation until onset GVHD | ||
| Median | 16 | 17 |
| Range | 8-40 | 6-33 |
| Median days of MP therapy | 11 | 15 |
| Range | 0-13 | 5-50 |
| Days from transplantation until visilizumab therapy | ||
| Median | 37 | 31 |
| Range | 13-50 | 13-55 |
| Characteristic . | Multidose . | Single dose . |
|---|---|---|
| No. of patients | 6 | 11 |
| Median age (y) | 40 | 24 |
| Range | 16-55 | 1-53 |
| Male/female | 6/0 | 4/7 |
| Diagnosis | ||
| ALL | 1 | 2 |
| AML/MDS | 2 | 6 |
| CML | 1 | 2 |
| NHL | 1 | 0 |
| Aplastic anemia | 1 | 0 |
| Osteopetrosis | 0 | 1 |
| Preparative regimen | ||
| Cy/TBI | 5 | 6 |
| Bu/Cy +/− ATG | 0 | 5 |
| Cy/ATG | 1 | 0 |
| GVHD prophylaxis | ||
| CSA/MTX | 6 | 9 |
| Tacrolimus/MTX | 0 | 1 |
| CSA/MP | 0 | 1 |
| Stem cell source | ||
| BM | 5 | 7 |
| PBSC | 1 | 3 |
| Cord blood | 0 | 1 |
| Donors | ||
| HLA-matched related | 3 | 1 |
| HLA-mismatched related | 1 | 1 |
| HLA-matched unrelated | 2 | 4 |
| HLA-mismatched unrelated | 0 | 5 |
| Days from transplantation until onset GVHD | ||
| Median | 16 | 17 |
| Range | 8-40 | 6-33 |
| Median days of MP therapy | 11 | 15 |
| Range | 0-13 | 5-50 |
| Days from transplantation until visilizumab therapy | ||
| Median | 37 | 31 |
| Range | 13-50 | 13-55 |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; ATG, antithymocyte globulin; CSA, cyclosporine; MTX, methotrexate; MP, methylprednisolone; BM, bone marrow; PBSC, peripheral blood stem cells.